查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2016279

RNA疗法市场：依治疗领域、递送系统和最终用户划分－2026年至2032年全球市场预测

RNA Therapy Market by Therapeutic Area, Delivery System, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025年RNA疗法市值为187.7亿美元，预计到2026年将成长至197亿美元，复合年增长率为6.40%，到2032年将达到289.9亿美元。

主要市场统计数据
基准年 2025 187.7亿美元
预计年份：2026年 197亿美元
预测年份 2032 289.9亿美元
复合年增长率 (%) 6.40%

这本全面的入门书籍说明了RNA 模式的进步、递送技术的创新以及法规环境的变化如何汇聚在一起，重新定义治疗方法开发途径。

RNA疗法领域已从单纯的科学探索转变为现代生物医学的核心要素，重塑了研究人员、临床医生和产业领袖参与治疗方法发现和开发的方式。传讯RNA、小干扰RNA、反义寡核苷酸及相关技术的进步，在多种适应症中展现出治疗潜力，推动了对平台技术、递送系统和专业生产能力的全新投资。这种转变体现在转化医学研发管线的加速发展、学术机构与产业界策略合作的加强，以及对可扩展和可重复生产流程日益增长的重视。

详细分析递送平台、临床优先排序和经营模式的突破如何共同重塑 RNA 治疗生态系统和商业化策略。

RNA疗法领域正经历一系列变革性转变，这些转变正在改变研发者和投资者的策略重点。首先，递送技术正成为关键的差异化因素。基于脂质奈米颗粒和新型外泌体平台的製剂能够实现以往难以实现的全身递送和组织靶向，而聚合物载体和病毒载体杂交体则提供了互补的方法，可实现持续表达和局部效应。这些递送技术的进步正在扩大可治疗的适应症范围，影响给药模式，并对生产要求产生重大影响。

对关税趋势将如何影响整个 RNA 疗法计画的供应链、筹资策略、临床重点和製造投资进行详细评估。

2025年美国可能对原产于美国的商品加征累积关税，这将为RNA疗法相关企业带来复杂的营运和策略挑战。关税趋势可能增加脂质、核苷酸、酵素和一次性耗材等关键原材料的到货成本，并可能影响质体生产、微流体封装、层析法系统以及无菌填充和包装生产线等昂贵设备的供应和价格。不断上涨的采购成本将迫使研发企业和契约製造製造商重新评估与供应商的关係、库存策略和采购区域，以确保按时完成专案并维持品质标准。

透过彻底调查不同治疗领域、递送平台权衡和最终使用者行为之间的差异，我们确定了 RNA 介入治疗计画的路线和发展重点。

细分领域的趋势揭示了科学机会与商业性可行性的交汇点，凸显了企业在推进基于RNA的干预疗法时必须面对的战术性选择。在考虑治疗领域细分时，研发人员需要在广泛适用性和特定适应症的复杂性之间取得平衡。心血管和代谢性疾病计画追求全身给药和持续作用；遗传疾病疗法旨在针对单基因疾病进行精准的基因校正和定序；感染疾病策略区分细菌和病毒感染的应对措施；神经系统疾病计画由于血脑障壁的限製而面临给药限制；肿瘤学疗法分为骨髓恶性肿瘤和固态肿瘤，二者在免疫肿瘤学方面存在差异；罕见疾病疗法则专注于高雪氏症、神经肌肉疾病和镰状贫血等特定疾病，这些疾病的临床终点和监管路径需要定制化的证据包。治疗领域的这种异质性导致了研发进度、安全性考量和商业性准入策略的差异。

对美洲、欧洲、中东和非洲以及亚太地区的生态系统如何对创新、製造能力、监管合规性和准入策略产生不同的影响进行全面的区域评估。

区域趋势正以不同的方式影响RNA疗法研发和商业化领域的商业决策。在美洲，强大的创业投资系统、领先的学术医疗中心和先进的製造基础设施为早期创新和快速临床应用提供了肥沃的环境。由国家监管机构管理的监管路径强调严格的安全性和有效性证据，而专业契约製造和服务供应商的集中则加快了能够连接这些网路的专案进入临床试验的时间。

本文深入分析了平台领导、策略伙伴关係、製造专业知识和监管合作如何使 RNA 治疗领域中最有效的组织脱颖而出。

在RNA疗法领域，领先的企业透过平台深度、策略伙伴关係和生产能力三者的组合来脱颖而出。以平台为中心的创新者正投资于基础技术，以实现跨多个适应症的快速迭代开发，并优先考虑模组化设计、可靠的表征方法以及用于支援监管咨询的资料包。合约开发和生产公司认识到，先进的技术能力是应对复杂RNA专案的竞争优势，因此正在扩展其在脂质体製剂、分析方法开发以及无菌填充和包装方面的专业服务。

为高阶主管提供实务指导，以协调平台选择、供应链韧性、监管参与和商业化准备，从而加速临床影响。

为了将科学突破转化为永续的治疗效果，产业领导者必须采取务实且协作的行动，在创新与营运严谨性之间取得平衡。应优先投资于与目标适应症相符的给药平台，确保製剂的选择既有生物证据支持，又具备下游生产的可行性。早期专案应包含分析方法开发和製程表征，以最大限度地减少后期阶段可能出现的意外问题，并缩短从研究到符合GMP规范生产的过渡时间。

对一种跨学科研究途径的透明说明，该方法结合了技术文献综述、监管分析、临床註册研究和主要专家访谈，以得出可靠的研究结果。

本研究整合了来自同行评审科学文献、监管指导文件、临床试验註册库、专利趋势、生产技术报告以及对行业高管、科学家和监管专家的访谈证据。透过跨资料来源的三角验证，本研究检验了技术趋势、给药平台的可行性以及营运限制，从而保持了分析的严谨性。定性访谈提供了有关决策流程、合作理由和生产考虑的背景信息，而二手资料则提供了对过往先例和监管变化的见解。

结论强调，要实现 RNA 技术的治疗潜力，需要将科学创新、製造成熟度和相关人员的参与结合起来。

RNA疗法正处于一个转折点，技术成熟、临床应用目标不断扩大以及监管预期不断演变，三者在此交汇，创造了巨大的转化应用机会。未来的进展将同样取决于分子设计和递送技术的创新，以及执行复杂生产专案、应对供应链波动和与整个医疗生态系统相关人员合作的组织能力。那些兼具卓越科研实力和前瞻性营运能力的机构，将能够推动治疗方法，满足未被满足的医疗需求，同时应对商业化和市场准入方面的实际挑战。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 RNA疗法市场：依治疗领域划分

  • 心血管疾病
  • 遗传性疾病
  • 感染疾病
    • 细菌感染疾病
    • 病毒感染疾病
  • 代谢性疾病
  • 神经系统疾病
  • 肿瘤学
    • 骨髓恶性肿瘤
    • 固体癌
  • 罕见疾病
    • 高雪氏症
    • 神经肌肉疾病
    • 镰状细胞贫血症

第九章 RNA疗法市场按递送系统划分

  • 外泌体
  • 脂质奈米颗粒
  • 聚合物载体
  • 病毒载体

第十章 RNA疗法市场：依最终用户划分

  • 生技公司
  • 医院和诊所
  • 製药公司
  • 研究机构

第十一章 RNA疗法市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章 RNA疗法市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章 RNA疗法市场：按国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章 美国RNA疗法市场

第十五章 中国RNA疗法市场

第十六章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Alnylam Pharmaceuticals, Inc.
  • Arcturus Therapeutics Holdings, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • BioNTech SE
  • CureVac NV
  • Eli Lilly and Company
  • Ionis Pharmaceuticals, Inc.
  • Moderna, Inc.
  • Sarepta Therapeutics, Inc.
  • Silence Therapeutics plc
  • Stoke Therapeutics
Product Code: MRR-0375F3EAA7E7

The RNA Therapy Market was valued at USD 18.77 billion in 2025 and is projected to grow to USD 19.70 billion in 2026, with a CAGR of 6.40%, reaching USD 28.99 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 18.77 billion
Estimated Year [2026] USD 19.70 billion
Forecast Year [2032] USD 28.99 billion
CAGR (%) 6.40%

Comprehensive primer explaining how advancements in RNA modalities, delivery innovations, and regulatory evolution are converging to redefine therapeutic development pathways

The field of RNA therapeutics has moved from scientific curiosity to a central pillar of contemporary biomedicine, reshaping how researchers, clinicians, and industry leaders approach treatment discovery and development. Advances in messenger RNA, small interfering RNA, antisense oligonucleotides, and related modalities have demonstrated therapeutic potential across a wide spectrum of indications, stimulating renewed investment in platform technologies, delivery systems, and specialized manufacturing capabilities. This transition is reflected in accelerated translational pipelines, strategic collaborations between academic institutions and industry, and a growing emphasis on scalable, reproducible production processes.

Technological maturation has been matched by evolving regulatory expectations and clinical evidence requirements, prompting developers to refine trial designs, safety monitoring approaches, and comparator choices. Meanwhile, improvements in delivery vectors, formulation chemistry, and analytical methods have reduced barriers to entry for new developers while raising the bar for differentiation. Consequently, organizations now prioritize platform robustness, cross-indication applicability, and the ability to demonstrate consistent performance across diverse patient populations.

As stakeholders evaluate next steps, the industry must integrate scientific progress with pragmatic operational planning. Manufacturing capacity, supply chain resilience, and regulatory engagement are now as critical as target selection and preclinical efficacy. In short, RNA therapeutics sits at a pivotal juncture where scientific promise must be matched by execution excellence to translate into durable clinical and commercial outcomes.

Detailed analysis of how breakthroughs in delivery platforms, clinical prioritization, and business models are jointly reshaping the RNA therapeutics ecosystem and commercialization strategies

The landscape for RNA therapeutics is undergoing a sequence of transformative shifts that alter strategic priorities for developers and investors alike. First, delivery science has emerged as a primary differentiator: formulations based on lipid nanoparticles and emerging exosome platforms are enabling systemic delivery and tissue targeting that were previously elusive, while polymer carriers and viral vector hybrids offer complementary approaches for sustained expression or localized effect. These delivery advances expand the range of treatable indications, influence dosing paradigms, and materially affect manufacturing requirements.

Second, there is a clear reorientation of clinical focus toward complex and previously intractable indications. Oncology programs increasingly explore RNA-mediated modulation of tumor biology and immune activation for both hematological malignancies and solid tumors, while rare disease efforts harness gene-silencing and replacement strategies to address genetic disorders such as Gaucher disease, neuromuscular disorders, and sickle cell disease. Infectious disease applications, including targeted approaches for viral infections and novel antibacterial RNA strategies, retain strategic importance given global public health priorities and the capability of RNA platforms to accelerate response timelines.

Third, the business model is shifting as platform-centric companies seek to monetize broad technology stacks through licensing, strategic alliances, and vertical integration. Contract development and manufacturing organizations are expanding capabilities to service high-containment production and lipid nanoparticle encapsulation, and hospitals and clinics are beginning to engage with advanced therapies in new ways as clinical delivery paradigms evolve. Research institutes continue to feed innovation, creating a dynamic innovation pipeline that is increasingly interdependent across sectors.

Finally, heightened attention to regulatory and payer evidence is reshaping go-to-market strategies. Developers are investing in real-world evidence generation, longitudinal safety monitoring, and health economics studies that support reimbursement discussions and policy adoption. Taken together, these shifts signal a transition from discrete, proof-of-concept achievements to sustained, system-level integration of RNA therapeutics into clinical practice.

In-depth assessment of how tariff developments can alter supply chains, sourcing strategies, clinical prioritization, and manufacturing investments across RNA therapeutic programs

The potential imposition of cumulative tariffs originating from the United States in 2025 presents a complex set of operational and strategic challenges for organizations involved in RNA therapeutics. Tariff dynamics can increase landed costs for critical raw materials such as lipids, nucleotides, enzymes, and single-use consumables, and they can also affect the availability and pricing of high-value capital equipment used for plasmid production, microfluidic encapsulation, chromatography systems, and sterile fill-finish lines. When procurement costs rise, developers and contract manufacturers are pressured to reassess supplier relationships, inventory strategies, and sourcing geographies to preserve program timelines and maintain quality standards.

In response to tariff-driven cost pressures, companies may accelerate efforts to localize supply chains, expanding domestic production of key inputs or negotiating longer-term procurement agreements to stabilize pricing. While localization can reduce exposure to cross-border tariffs, it often requires significant capital investment and operational lead time, particularly when specialized manufacturing attributes or regulatory approvals are necessary. As a result, smaller developers and research institutes that lack in-house production capabilities may be disproportionately affected, compelling greater reliance on regional contract manufacturers and strategic partners.

Tariffs can also influence clinical development decisions. Increased input costs may cause sponsors to optimize trial designs to reduce material usage per patient, to prioritize indications with clearer pathways to reimbursement, or to sequence programs based on resource intensity. For hospitals and clinics, procurement budgets could be squeezed, potentially affecting adoption cycles for advanced therapies that require complex delivery or supportive infrastructure. Investors and strategic partners will therefore scrutinize the resilience of supply chain plans and the feasibility of production scale-up under altered cost structures.

Finally, the political and regulatory signaling associated with tariff policy can have reputational and strategic implications. Heightened trade tensions may encourage multinational firms to diversify manufacturing footprints across multiple regions to avoid exposure to single-jurisdiction policy shifts. At the same time, bilateral and multilateral dialogues can create pathways for exemptions or tariff mitigation mechanisms for critical healthcare supplies, underscoring the importance of active engagement with policymakers and industry associations. In short, tariff developments in 2025 could catalyze structural adjustments across procurement, manufacturing strategy, and clinical program prioritization, with tangible implications for timelines and partnership models.

Rigorous exploration of therapeutic area distinctions, delivery platform trade-offs, and end-user behaviors that together define program pathways and development priorities for RNA interventions

Segment-level dynamics reveal where scientific opportunity and commercial viability intersect, and they illuminate the tactical choices organizations must confront when advancing RNA-based interventions. Examining therapeutic area segmentation, developers are balancing broad applicability against indication-specific complexity: cardiovascular and metabolic disorder programs pursue systemic delivery and sustained activity, genetic disorder initiatives target precise gene correction or silencing for monogenic conditions, infectious disease strategies differentiate between bacterial approaches and viral infection countermeasures, neurological programs grapple with blood-brain barrier delivery constraints, oncology efforts split between hematological malignancies and solid tumors with differing immuno-oncology considerations, and rare disease pursuits concentrate on specific conditions such as Gaucher disease, neuromuscular disorders, and sickle cell disease where clinical endpoints and regulatory pathways demand bespoke evidence packages. This therapeutic heterogeneity drives divergent development timelines, safety considerations, and commercial access strategies.

When viewed through the lens of delivery system segmentation, contrasts become even more pronounced. Exosome-based strategies promise biologically native delivery and potential immune stealth but face manufacturing and characterization challenges that require advanced analytical capacity. Lipid nanoparticle technologies have become the de facto solution for many systemic applications due to demonstrated scalability and established regulatory precedents, yet they demand rigorous control of excipients and process parameters. Polymer carriers offer tunable release profiles and modular design but frequently require extensive biocompatibility validation, while viral vectors deliver robust transgene expression for certain applications at the cost of immunogenicity and complex regulatory scrutiny. The choice of delivery platform not only affects clinical performance but also determines upstream supplier needs, facility design, and the depth of analytical development required for regulatory submissions.

End-user segmentation shapes commercialization and adoption strategies in practical ways. Biotechnology companies often lead innovation and platform development, focusing on intellectual property creation and clinical proof of concept. Pharmaceutical companies bring late-stage development, regulatory experience, and global commercialization infrastructure, enabling broader market access when clinical and payer evidence align. Hospitals and clinics play a critical role in adoption for therapies that require specialized administration, long-term monitoring, or integration into existing care pathways, and their procurement criteria increasingly emphasize demonstrable clinical benefit and operational feasibility. Research institutes remain essential sources of discovery and translational expertise, frequently partnering with industry to de-risk early science and catalyze new platform iterations.

Taken together, these segmentation insights underscore the necessity of aligning therapeutic targets, delivery choices, and end-user engagement strategies early in program planning. Developers that explicitly account for the interplay among indication characteristics, platform constraints, and end-user requirements are better positioned to design clinical programs that meet regulatory expectations and accelerate acceptance in clinical practice.

Comprehensive regional appraisal of how Americas, EMEA, and Asia-Pacific ecosystems differentially influence innovation, manufacturing capacity, regulatory navigation, and access strategies

Regional dynamics shape the operational calculus for research, development, and commercialization of RNA therapies in distinct ways. In the Americas, robust venture capital ecosystems, leading academic medical centers, and advanced manufacturing infrastructure provide a fertile environment for early-stage innovation and rapid clinical translation. Regulatory pathways administered by national authorities emphasize rigorous safety and efficacy evidence, and the concentration of specialized contract manufacturers and service providers reduces time-to-clinic for programs that can access these networks.

Europe, the Middle East, and Africa present a mosaic of regulatory regimes and payer structures that require nuanced market access planning. The European regulatory framework promotes centralized review pathways that can support cross-border approvals, while health systems across the region emphasize cost-effectiveness and real-world therapeutic value. Emerging markets within the region are experiencing growing biotech activity and clinical trial participation, offering opportunities for enrollment and partnership but necessitating tailored regulatory and reimbursement strategies.

Asia-Pacific is characterized by rapid capacity expansion, substantial public and private investment in biopharmaceutical manufacturing, and an increasing number of skilled scientific and technical personnel. Several jurisdictions are actively streamlining regulatory processes for advanced therapies and incentivizing domestic production, which can accelerate timelines for locally developed programs. Nevertheless, regional supply chain dependencies and variable regulatory harmonization require companies to adopt diversified sourcing approaches and proactive regulatory engagement to ensure smooth program progression across multiple jurisdictions.

Insightful summary of how platform leadership, strategic alliances, manufacturing specialization, and regulatory engagement distinguish the most effective organizations in RNA therapeutics

Leading organizations operating in the RNA therapeutics domain differentiate themselves through a combination of platform depth, strategic partnerships, and manufacturing capabilities. Platform-centric innovators invest in foundational technologies that enable rapid iteration across multiple indications, prioritizing modular design, robust characterization methods, and data packages that support regulatory discussions. Contract developers and manufacturers are expanding specialized services for lipid nanoparticle formulation, analytical method development, and aseptic fill-finish, recognizing that deep technical capability is a competitive advantage when serving complex RNA programs.

Collaborative models have become central to business strategies. Strategic alliances between technology developers and larger pharmaceutical organizations enable resource pooling for late-stage development and global commercialization, while academic and clinical partnerships accelerate translational research and facilitate patient access for early trials. Some organizations pursue vertical integration to secure critical inputs and reduce exposure to external supply volatility, whereas others focus on niche specialization-such as exosome isolation or polymer carrier chemistry-to command unique value propositions.

Operational excellence is increasingly visible in the firms that succeed in this space. Companies that have invested early in scalable analytics, robust process controls, and regulatory science expertise move more efficiently through clinical development and engage payers more credibly. Additionally, those that cultivate open channels with regulators and health technology assessment bodies tend to reduce approval friction and achieve smoother reimbursement discussions. In aggregate, the industry favors entities that combine scientific leadership with pragmatic execution capabilities across manufacturing, regulatory, and commercial functions.

Action-oriented guidance for executives to align platform selection, supply chain resilience, regulatory engagement, and commercialization readiness to accelerate clinical impact

To convert scientific breakthroughs into sustainable therapeutic impact, industry leaders must adopt pragmatic, coordinated actions that balance innovation with operational rigor. Prioritize investment in delivery platforms that align with targeted indications, ensuring that formulation choices are justified by both biological rationale and downstream manufacturing feasibility. Early-stage programs should incorporate analytical development and process characterization to minimize late-stage surprises and to shorten timelines when transitioning from research to GMP production.

Strengthening supply chain resilience is essential. Companies should evaluate dual-sourcing strategies for critical raw materials, consider regional manufacturing options to mitigate cross-border policy exposure, and negotiate long-term agreements that secure access to specialized consumables. Simultaneously, organizations should pursue strategic collaborations with contract developers and academic centers to de-risk technical hurdles while maintaining flexibility in portfolio decision-making.

Engagement with regulators, payers, and clinical stakeholders must begin early and continue iteratively. Developers should design clinical programs that capture endpoints meaningful to both regulators and reimbursement authorities, and they should invest in real-world evidence infrastructures that demonstrate long-term value. Finally, cultivate a disciplined approach to commercialization by aligning clinical development pathways with realistic operational capabilities, thereby ensuring that scientific advances can be delivered reliably to patients at scale.

Transparent description of the multidisciplinary research approach combining technical literature review, regulatory analysis, clinical registry inspection, and primary expert interviews for robust insight generation

This research synthesizes evidence from peer-reviewed scientific literature, regulatory guidance documents, clinical trial registries, patent landscapes, manufacturing technology reports, and primary interviews with industry executives, scientists, and regulatory experts. Analytical rigor was maintained through triangulation across data sources to validate technology trends, delivery platform feasibility, and operational constraints. Qualitative interviews provided context on decision-making processes, partnership rationales, and manufacturing considerations, while secondary sources informed historical precedent and regulatory evolution.

Methodological safeguards included cross-validation of technical claims with multiple domain experts, verification of manufacturing and formulation challenges against facility design documentation, and careful attention to regulatory language to ensure accurate interpretation of approval pathways. The approach prioritized disclosure of assumptions and sought to isolate practice patterns from transient events, thereby focusing on durable trends with operational relevance. Throughout the study, emphasis was placed on actionable insight rather than speculative projection, enabling practitioners to apply findings directly to program planning and strategic decision-making.

Concluding synthesis emphasizing the necessity of combining scientific innovation, manufacturing maturity, and stakeholder engagement to realize the therapeutic potential of RNA technologies

RNA therapeutics stand at an inflection point where technological maturity, expanding clinical ambition, and evolving regulatory expectations converge to create substantial translational opportunity. Continued progress will depend not only on innovations in molecular design and delivery but equally on the ability of organizations to execute complex manufacturing campaigns, manage supply chain dynamics, and engage stakeholders across the healthcare ecosystem. Those that integrate scientific excellence with operational foresight will be positioned to advance therapies that address unmet medical needs while navigating the practical realities of commercialization and access.

As the field progresses, attention to platform reproducibility, end-user integration, and evidence generation will determine which programs achieve clinical adoption and sustained impact. The coming years will likely favor multidisciplinary teams that combine molecular biology, formulation chemistry, process engineering, and regulatory science to convert laboratory breakthroughs into reliable, scalable treatments for patients.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. RNA Therapy Market, by Therapeutic Area

  • 8.1. Cardiovascular Diseases
  • 8.2. Genetic Disorders
  • 8.3. Infectious Diseases
    • 8.3.1. Bacterial Infections
    • 8.3.2. Viral Infections
  • 8.4. Metabolic Disorders
  • 8.5. Neurological Disorders
  • 8.6. Oncology
    • 8.6.1. Hematological Malignancies
    • 8.6.2. Solid Tumors
  • 8.7. Rare Diseases
    • 8.7.1. Gaucher Disease
    • 8.7.2. Neuromuscular Disorders
    • 8.7.3. Sickle Cell Disease

9. RNA Therapy Market, by Delivery System

  • 9.1. Exosomes
  • 9.2. Lipid Nanoparticles
  • 9.3. Polymer Carriers
  • 9.4. Viral Vectors

10. RNA Therapy Market, by End User

  • 10.1. Biotechnology Companies
  • 10.2. Hospitals & Clinics
  • 10.3. Pharmaceutical Companies
  • 10.4. Research Institutes

11. RNA Therapy Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. RNA Therapy Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. RNA Therapy Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States RNA Therapy Market

15. China RNA Therapy Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Alnylam Pharmaceuticals, Inc.
  • 16.6. Arcturus Therapeutics Holdings, Inc.
  • 16.7. Arrowhead Pharmaceuticals, Inc.
  • 16.8. BioNTech SE
  • 16.9. CureVac N.V.
  • 16.10. Eli Lilly and Company
  • 16.11. Ionis Pharmaceuticals, Inc.
  • 16.12. Moderna, Inc.
  • 16.13. Sarepta Therapeutics, Inc.
  • 16.14. Silence Therapeutics plc
  • 16.15. Stoke Therapeutics

LIST OF FIGURES

  • FIGURE 1. GLOBAL RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RNA THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL RNA THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL RNA THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RNA THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL RNA THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL RNA THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL RNA THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL RNA THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RNA THERAPY MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL RNA THERAPY MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL RNA THERAPY MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RNA THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RNA THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RNA THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RNA THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RNA THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RNA THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RNA THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RNA THERAPY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RNA THERAPY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RNA THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RNA THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RNA THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RNA THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RNA THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RNA THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RNA THERAPY MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RNA THERAPY MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RNA THERAPY MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RNA THERAPY MARKET SIZE, BY GAUCHER DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RNA THERAPY MARKET SIZE, BY GAUCHER DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RNA THERAPY MARKET SIZE, BY GAUCHER DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RNA THERAPY MARKET SIZE, BY SICKLE CELL DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RNA THERAPY MARKET SIZE, BY SICKLE CELL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RNA THERAPY MARKET SIZE, BY SICKLE CELL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RNA THERAPY MARKET SIZE, BY EXOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RNA THERAPY MARKET SIZE, BY EXOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RNA THERAPY MARKET SIZE, BY EXOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RNA THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RNA THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RNA THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL RNA THERAPY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL RNA THERAPY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL RNA THERAPY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RNA THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL RNA THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL RNA THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL RNA THERAPY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL RNA THERAPY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL RNA THERAPY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL RNA THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL RNA THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL RNA THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL RNA THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS RNA THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL RNA THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. GCC RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GCC RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 141. GCC RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 142. GCC RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. GCC RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 144. GCC RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 145. GCC RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. G7 RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. G7 RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 162. G7 RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 163. G7 RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. G7 RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 165. G7 RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 166. G7 RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. NATO RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. NATO RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 169. NATO RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 170. NATO RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. NATO RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 172. NATO RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 173. NATO RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)